Galanin
Also known as: GAL, galanin peptide, human galanin, porcine galanin, neuropeptide galanin, galaninergic peptide
Endogenous neuropeptide / neuroendocrine signaling peptide; acts as agonist at GalR1, GalR2, and GalR3 G protein-coupled receptors
What it is
People interested in neuropeptide research, metabolic health, mood disorders, and neurological conditions are increasingly curious about galanin — a natural peptide that the brain and body produce to regulate pain, mood, memory, appetite, and stress responses. Researchers are studying whether galanin-based drugs could address epilepsy, depression, Alzheimer disease, and metabolic disorders.
The scientific side
galanin is a 30-amino-acid neuropeptide that exerts its biological effects through three G protein-coupled receptor subtypes — GalR1, GalR2, and GalR3 — each with distinct signaling profiles. GalR1 and GalR3 couple primarily to Gαi/o proteins, inhibiting adenylyl cyclase and reducing intracellular cyclic AMP, while GalR2 couples to Gαq/11, activating phospholipase C and triggering intracellular calcium release. GalR2 also engages β-arrestin2-dependent signaling independent of G proteins, enabling functional selectivity relevant to biased agonist drug design. These receptors are broadly distributed in the central nervous system — across the locus coeruleus, hypothalamus, amygdala, hippocampus, and spinal cord — and in peripheral tissues including the pancreas, gastrointestinal tract, and heart. In the brain, galanin functions as a state-dependent co-transmitter and circuit stabilizer, modulating neuronal excitability and neuroendocrine output. It is co-expressed with norepinephrine in locus coeruleus neurons and serotonin in raphe nuclei. Under conditions of heightened neuronal activity — such as seizures — galanin is released and provides inhibitory feedback via GalR1/GalR3-mediated hyperpolarization. This anticonvulsant mechanism underpins interest in galanin analogs for temporal lobe epilepsy, where GalR1 and GalR2 activation reduces seizure propagation in experimental models. Galanin also modulates metabolic homeostasis. Circulating galanin is significantly elevated in patients with type 2 diabetes mellitus, and in the pancreas galanin suppresses insulin secretion. Galanin/GALR2 signaling appears to bridge the shared pathophysiology linking type 2 diabetes to Alzheimer's disease through modulation of insulin resistance pathways and neuroinflammation in preclinical models. In mood disorders, cerebrospinal fluid galanin is elevated in major depressive disorder, and psilocybin therapy selectively reduced CSF galanin alongside noradrenaline, implicating galaninergic normalization as a pharmacodynamic signature of rapid antidepressant action. In oncology, tumor-secreted galanin recruits immunosuppressive myeloid-derived suppressor cells via GALR3 in glioblastoma, conferring ferroptosis resistance and attenuating antitumor immunity, while combining GALR3 inhibition with anti-PD-1 therapy produced durable tumor regression in mouse models. Conversely, in spinal cord injury, galanin shifts microglial polarization from pro-inflammatory M1 toward anti-inflammatory M2 states via TRPV1/CaMKII/NRF2 signaling through GALR2, reducing secondary inflammation in preclinical studies.
Class: Endogenous neuropeptide / neuroendocrine signaling peptide; acts as agonist at GalR1, GalR2, and GalR3 G protein-coupled receptors
Administration & storage
- Administration
- Intracerebroventricular (ICV) injection used in rodent CNS studies for direct CNS deliveryIntravenous injection used in animal pharmacology studiesIntrathecal infusion studied in preclinical models for spinal cord targetsSubcutaneous injection of galanin analogs investigated in preclinical metabolic studiesPeripheral intraperitoneal injection in some animal studies
- Storage
- Synthetic galanin peptide (research grade): store lyophilized powder at -20°C, protected from light and moisture. Reconstituted solutions should be aliquoted to avoid freeze-thaw cycles and stored at -80°C for long-term stability or at -20°C for short-term use. Solutions in aqueous buffers are susceptible to aggregation; working solutions should be freshly prepared or used within weeks.
- Cautions
- Galanin is not approved for human therapeutic use; there is no established safe dosing range in humans.,Galanin exerts context-dependent, often opposing effects depending on receptor subtype engaged and brain region involved — constituting the 'Galanin Dilemma.' Non-selective activation could simultaneously produce both beneficial (neuroprotective, anticonvulsant) and detrimental (tumor-promoting, cognitive-impairing) effects.,Galanin suppresses insulin secretion from pancreatic islets and elevates blood glucose (hyperglycemic effect observed in early animal studies). Individuals with diabetes or glycemic instability face potential metabolic risk from any galaninergic intervention.,GALR3 activation promotes immunosuppression and supports tumor immune evasion in glioblastoma. Indiscriminate galanin receptor activation could theoretically impair anti-tumor immune surveillance.,Galanin modulates cardiovascular function and renal homeostasis through peripheral receptor expression. Cardiovascular monitoring would be required in any human dosing study.,Exogenous galanin peptide has very limited blood-brain barrier penetration due to its peptide structure, limiting CNS bioavailability by systemic routes without specialized delivery systems or analogs with enhanced CNS penetration.,No human safety, pharmacokinetic, or tolerability data exist for exogenously administered galanin. Any extrapolation from preclinical dosing to humans is unsupported.
Legal & regulatory status
Galanin itself is not approved by the US FDA as a drug. No galanin-based therapeutic has received FDA approval. Galanin is studied as a naturally occurring endogenous neuropeptide and as a research target; several…
Galanin is not currently listed on the WADA Prohibited List as a prohibited substance for competitive athletes. However, as an endogenous neuropeptide with potential metabolic and neuroendocrine effects, any exogenously…
Galanin is not approved by Health Canada as a therapeutic product. No galanin-based drug has received a Notice of Compliance (NOC) or Drug Identification Number (DIN) in Canada. Galanin and its receptor-targeting…
What it's studied for
- Epilepsy — anticonvulsant neuropeptide modulation, temporal lobe epilepsy Preclinical (Animal)
- Major depressive disorder — role as CSF biomarker and pharmacodynamic target Human observational
- Type 2 diabetes mellitus — circulating biomarker and metabolic modulator Human observational
- Alzheimer's disease and cognitive decline — galaninergic dysregulation and potential GALR2 therapeutic target Preclinical (Animal)
- Glioblastoma — role in tumor immunosuppression and GALR3-targeted combination immunotherapy Preclinical (Animal)
- Spinal cord injury — neuroprotection and neuroinflammation modulation Preclinical (Animal)
- Inflammatory bowel disease — GALR2 biased agonism as anti-inflammatory strategy Preclinical (Animal)
- Polycystic ovary syndrome (PCOS) — circulating galanin as biomarker Human observational
- Schizophrenia — serum galanin as potential diagnostic biomarker Human observational
- Endometrial cancer — serum galanin as diagnostic biomarker for endometrial neoplasia Human observational
Safety signals
- Hyperglycemia and impaired insulin secretion
- Context-dependent pro-tumor effects via GALR3 activation — immunosuppression in glioblastoma
- Cognitive impairment risk via cholinergic inhibition — overexpression in Alzheimer's disease neurons may exacerbate acetylcholine deficit
- Opposing receptor-subtype effects — non-selective galanin receptor activation may simultaneously produce beneficial and detrimental outcomes depending on tissue context
- Cardiovascular and renal function modulation — galanin receptors expressed in heart and kidney; potential hemodynamic effects
- Mood and stress dysregulation — galanin/noradrenaline co-transmission in locus coeruleus; elevated CSF galanin in depression; risk of disrupting stress resilience circuitry
- Lack of human pharmacokinetic and safety data — no established safe dose range or tolerability profile in humans
All studies (4)
Frequently asked
Is galanin available as a supplement or injectable peptide for self-use?
Galanin is not an approved drug or supplement in any jurisdiction. While synthetic galanin peptide is available from research chemical suppliers for laboratory use, it has no established human dosing protocol, no published human safety data, and no regulatory approval anywhere. Unlike some research peptides that have at least preliminary human trials, galanin-based therapeutics remain entirely in preclinical and mechanistic research stages. Self-administration would involve unknown and potentially serious risks.
What conditions is galanin being researched for?
Based on published research literature, galanin and its receptor system are actively studied in relation to: epilepsy and seizure control (anticonvulsant effects in animal models), major depressive disorder (CSF biomarker role), type 2 diabetes and metabolic dysregulation, Alzheimer's disease and cognitive decline, glioblastoma and tumor immunotherapy, spinal cord injury neuroprotection, inflammatory bowel disease, polycystic ovary syndrome (as a biomarker), schizophrenia (as a biomarker), and endometrial cancer (as a diagnostic biomarker). Most of this research is at the preclinical or observational human stage, and no galanin-based drug has been approved for any of these conditions.
Does galanin help with mood, depression, or anxiety?
Galanin plays a documented role in regulating mood-related neurocircuits. It is co-expressed with norepinephrine in locus coeruleus neurons and its levels are elevated in the cerebrospinal fluid of people with major depressive disorder. A human study found that psilocybin therapy selectively reduced CSF galanin in MDD patients, suggesting the galaninergic system is involved in depressive state biology. However, no approved galanin-based treatment exists for depression or anxiety, and no human clinical trial has tested exogenous galanin as an antidepressant. Current evidence is observational and mechanistic only.
What are the galanin receptor subtypes and why do they matter?
There are three galanin receptor subtypes: GalR1, GalR2, and GalR3. GalR1 and GalR3 are coupled to inhibitory Gαi/o proteins (reducing cellular cAMP), while GalR2 is coupled to Gαq/11 (activating phospholipase C and calcium signaling) and can also signal via β-arrestin2 in a G protein-independent manner. This receptor diversity explains why galanin can have opposing effects in different tissues — for example, GALR2 activation may be neuroprotective and anti-inflammatory in spinal cord injury, while GALR3 activation promotes tumor immunosuppression in glioblastoma. Developing receptor-subtype-selective drugs is considered critical to translating galanin research into safe therapies.
Can galanin affect blood sugar or insulin?
Yes — galanin has documented metabolic effects. In the pancreas, galanin suppresses insulin secretion from islet cells, and animal studies showed it produces hyperglycemia. Meta-analyses of human observational studies show that circulating galanin levels are significantly elevated in patients with type 2 diabetes compared with non-diabetic controls. These findings suggest galaninergic dysregulation contributes to metabolic dysfunction, though the direction of causality is unclear. No clinical intervention based on galanin modulation is currently approved for metabolic disorders.